HFpEF management

Q: What does the research say about HFpEF management?

The scientific consensus on HFpEF management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims.

Q: What do clinical guidelines recommend for HFpEF management?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What does the research say about HFpEF management?

Emerging pathwayBased on 100 analyzed claims

Emerging evidence with 100 primary claims

Journal clubs discussing HFpEF management

Recent sessions

Inflammatory Hypothesis of CAD

STEMI Management — Wed, Aug 12, 8:00 AM EDT — 7 attended

New data on Heart Failure Intervention

Synapse Team — Thu, Jul 16, 4:00 PM EDT

Sessions from public journal clubs on Synapse. RSVP to join the live discussion.

New research on HFpEF management

The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality

Cardiology — Kleiner‐Shochat M — Oct 2020

Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease

Journal of Epidemiology & Community Health — Gemmell I — Nov 2005

Impact of Statins on Cellular Respiration and De-Differentiation of Myofibroblasts in Human Failing Hearts

ESC Heart Failure — Emelyanova L — Sep 2019

The diagnostic utility of brain natriuretic peptide in heart failure patients presenting with acute dyspnea: a meta-analysis

Clinical Chemistry and Laboratory Medicine (CCLM) — Mastandrea P — Nov 2012

Troponin: an important prognostic biomarker in patients with heart failure and reduced ejection fraction?

European Journal of Heart Failure — Yafasova A — Jun 2021

Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

Circulation — Nov 2021

Extending palliative care to patients with heart failure

British Journal of Hospital Medicine — Johnson M — Jan 2010

Treating depression in patients with heart failure: what is (not) recommended?

European Journal of Preventive Cardiology — Herrmann‐Lingen C — May 2022

Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook

Expert Review of Cardiovascular Therapy — Latini R — Feb 2016

Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure

Revista Portuguesa de Cardiologia — Silva‐Cardoso J — Mar 2019

Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction

Cardiovascular Research — Dulce R — Jun 2022

PARADIGM-HF — The Experts' Discussion

New England Journal of Medicine — Jessup M — Sep 2014

Stay current on HFpEF management

Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.

Journal Club takes on HFpEF management

“Statin therapy significantly reduces cardiovascular events in individuals with elevated hs-CRP levels.”
Inflammatory Hypothesis of CADSTEMI Management · Aug 12, 2026

Evidence brief: HFpEF management

HFpEF management (also known as HFpEF, diastolic heart failure, preserved EF). Heart failure with preserved ejection fraction

As of 2026-08-18, the scientific consensus on HFpEF management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on HFpEF management. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hfpef-management.

Deterministic synthesis from Synapse's enriched corpus — 203 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for HFpEF management?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.